Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
Filed with HKEX · Stock code 6998 · · 2 pages · English
Edding Genor Group Holdings Limited on 6ix
Earlier from Edding Genor
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- 2026 Interim Report
- EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
- Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
Later from Edding Genor
All Edding Genor news releasesFollow Edding Genor into a list and get an email when it puts out news.
Follow Edding Genor